2.909EUR-0.29%Mkt Cap: —P/E: —1d ago
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese ence…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value698.34M $
Revenue (TTM)155.37M $
Gross Profit-64.84M $
Net Income (TTM)-171.36M $
Revenue/Share0.8707 USD
Last Price2.909 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees620
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINFR0004056851
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-6.51
EV/Revenue4.49
P/S—
P/B6.82
EPS (TTM)-0.71
EPS (Forward)—
52W Range
2.83424% of range3.140
52W High3.140 EUR
52W Low2.834 EUR
Profitability
Gross Margin-41.73%
Oper. Margin-74.92%
EBITDA Margin-69.07%
Profit Margin-110.29%
ROE-117.85%
ROA-16.68%
Growth
Revenue Growth-27.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-60.54M $
CapEx (TTM)—
FCF Margin-29.73%
FCF Yield—
Net Debt96.42M $
Net Debt/EBITDA-0.90
Balance Sheet
Debt/Equity259.16
Current Ratio2.16
Quick Ratio1.33
Book Value/Sh0.4280 EUR
Cash/Share0.6410 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.76.50M
Float157.26M
Insiders10.72%
Institutions24.42%
Technical
SMA 503.757 (-22.6%)
SMA 2005.414 (-46.3%)
Beta1.35
S&P 52W Chg20.80%
Avg Vol (30d)250.14K
Avg Vol (10d)69.25K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—